Who decides how inspection results are interpreted and who decides how an inspection becomes classified as
The following article by Redica Systems Senior GMP Quality Expert Jerry Chapman contains insights for
Is your company trying to get new drugs approved in Brazil? In this article, originally published
FDA recently posted a 38-page form 483 issued to Novel Laboratories, Inc d.b.a. LUPIN, located in
December is generally a slow time when it comes to posting of FDA Warning Letters. Nevertheless, on Dec.
The week of the U.S. Thanksgiving holiday was yet again another week that was light on Warning Letter
Did the pandemic reduce the 483 issuance risk from pre-approval inspections (PAIs)? That is how it
A comprehensive GMP intelligence program includes monitoring health authority enforcement actions including
In November 2019 FDA issued an unusual warning letter to Greenbrier International Inc (doing business as
Presented by Jerry Chapman on October 29, 2020
What you will learn:
Enter your email address and someone will contact you shortly to customize your insights.
Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.
INDEX INFORMATION Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.
STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.
ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.
Enter your email address and someone will contact you shortly to customize your report.
Enter your email address and someone will contact you shortly to customize your report.
Enter your email address and someone will contact you shortly to customize your report.
Enter your email address and someone will contact you shortly to get you started.
Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.
Enter your email address and someone will contact you shortly to explore enforcement trends.
Enter your email address and someone will contact you shortly to explore observations and trends.
Enter your email address and someone will contact you shortly to run your custom report.
Enter your email address and someone will contact you shortly to customize your report.
Enter your email address and someone will contact you shortly to get the reports and analysis you need.
In this summary we identify:
In this summary we identify:
FY2018-FY2020 GMP data for Lonza & Catalent
Top GMP primary citations
Top FDA 483 observations
Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates
Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.
Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble
What you will learn:
Enter your email address and someone will contact you shortly to answer all of your questions and get you started.
Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate
Get instant access to the webinar video and slides.
What you will learn:
In this summary we identify:
GMP data from FY2017 to FY2020 for the Asia-Pacific region
Top 3 GMP primary and secondary citations
In this summary we identify:
SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.
WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject
SITES Quickly assess inspection records including dates and inspectors across all of your sites
INSPECTIONS Complete list of FDA inspections by date, company, category, and country
Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.
Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.
Sign up for your FREE account today and get instant access to Enforcement Analytics.
Presented by Steve Greer on June 23, 2020
What you will learn:
What You Will Learn from This Report:
The first countrywide import alert issued by FDA
An inadequate deviation investigation
An inadequate product specifications and a product recall
Process validation issues at a CMO
A different perspective on process validation and the culpability of the quality unit
What You Will Learn from This Report:
How a major pharmaceutical company designed a program to train future leaders in quality
An industry-led initiative to advance the state of quality in the pharma industry
A pharma GMP leader’s tips for supporting quality culture within an organization
An update on FDA’s Quality Maturity Model
Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020
What you will learn:
Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp
What you will learn:
Presented by Redica Systems
What you will learn:
What You Will Learn from This Report:
The latest U.S. and European regulatory developments
The impact of smart combination products
How the EU MDR impacts drug-device combination products
What You Will Learn from This Report:
In-depth analysis of the findings
Lessons learned
How companies can avoid similar shortcomings.
Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.
Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.
Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.
What You Will Learn from This Sample:
See how a 510(k) submission is structured
Find out what information to include
Review correspondence between sponsor and FDA
Enter your email address and someone will contact you shortly.
Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman
What you will learn:
Enter your email address and someone will contact you shortly to get the reports and analysis you need.
Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and Human Factors, Kaleidoscope Innovation
What you will learn:
Let us know who you are and we’ll be in touch to answer all of your questions and get you started.
Enter your email address and someone will contact you shortly.
Enter your email address and someone will contact you shortly.
Enter your email address and someone will contact you shortly.
Enter your email address and someone will contact you shortly.
Enter your email address and someone will contact you shortly.
Enter your email address and someone will contact you shortly to get the data and analysis you need.
Enter your email address and someone will contact you shortly to get the data and analysis you need.
Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.
Eliminate days of work and get your FREE personalized 483 Observation Report.